PROVO, Utah — May 7, 2026 — Nu Skin Enterprises Inc. (NYSE: NUS) today announced first quarter revenue results within its guidance range. Executive Summary Q1 2026 vs. Prior-year Quarter | Revenue | $320.6 million; (12.0)%· +1.1% FX impact or $3.9…
PROVO, Utah — May 7, 2026 — Nu Skin Enterprises Inc. (NYSE: NUS) today announced first quarter revenue results within its guidance range.
Executive Summary
Q1 2026 vs. Prior-year Quarter
| Revenue | $320.6 million; (12.0)%· +1.1% FX impact or $3.9 million |
| Earnings Per Share (EPS) | $0.04 or $0.14 excluding certain charges compared to $2.14 or $0.23 excluding one-time gain from Mavely sale and other charges |
| Customers | 669,535; (14)% |
| Paid Affiliates | 120,850; (8)% |
| Sales Leaders | 26,915; (13)% |
“We delivered first quarter revenue in line with our expectations and made further progress in our strategic priorities while operating in a volatile environment,” said Ryan Napierski, Nu Skin president and CEO. “As we move through 2026, we are focused on empowering our sales leaders to scale our intelligent wellness platform with our latest innovation, Prysm iO™, ahead of our full consumer rollout in the second half. We also continue to invest in laying the groundwork to expand our presence in emerging markets, including the formal launch of India anticipated in late 2026, while continuing to improve our operational discipline to return value to shareholders.
“We are encouraged by early signs of improving paid affiliates and new sales leader development in several markets as our leaders begin integrating Prysm iO into their businesses and continue to build upon our leading anti-aging Tru Face® brand. We are focused on partnering with our sales force on leveraging the proprietary nutritional health biomarker tracking from Prysm iO to expand the channel as we prepare to drive customer subscriptions for our wellness products. While these initiatives will take time to develop, we remain confident that they will increase sales leader engagement and expand our global reach over time to drive the next phase of growth for Nu Skin.”
Q1 2026 Year-over-year Operating Results
| | |
| --- | --- |
| Revenue | $320.6 million compared to $364.5 million· +1.1% FX impact or $3.9 million |
| Gross Margin | 66.9% or 67.9% excluding certain charges compared to 67.8%· Nu Skin business was 76.9% compared to 76.7% |
| Selling Expenses | 34.3% compared to 32.5%· Nu Skin business was 40.5% compared to 38.7% |
| G&A Expenses | 30.7% or 29.9% excluding certain charges compared to 31.1% or 28.9% excluding certain charges |
| Impairment Expenses | $1.8 million impairment compared to $25.1 million impairment |
| Operating Margin | 1.3% or 3.6% excluding certain charges compared to (2.7)% or 6.4% excluding impairment and other charges |
| Interest Expense | $4.3 million compared to $3.3 million |
| Other Income (Expense) | $2.8 million compared to $(28.4) million· Prior year reflects $28.1 million unrealized loss on investment |
| Income Tax Rate | 29.4% compared to 20.1% |
| EPS | $0.04 or $0.14 excluding certain charges compared to $2.14 or $0.23 excluding one-time gain from Mavely sale and other charges |
**
Stockholder Value**
| | |
| --- | --- |
| Dividend Payments | $2.9 million |
| Stock Repurchases | $5.0 million· $137.3 million remaining in authorization |
Q2 and Full-year 2026 Outlook
| | |
| --- | --- |
| Q2 2026 Revenue | $330 to $360 million; (15)% to (7)%· Approximately 0% FX impact |
| Q2 2026 EPS | $0.15 to $0.25 |
| 2026 Revenue | $1.35 to $1.50 billion; (9)% to 1%· Approximately (1)% FX impact |
| 2026 EPS | $0.70 to $1.10 or $0.80 to $1.20 excluding certain charges |
“In addition to delivering on revenue and adjusted earnings, we returned $8 million to shareholders in the form of dividends and share repurchases,” said Chelsea Lantz, interim chief financial officer. “We were also able to refinance our debt, extending our liquidity as we invest in growth initiatives and navigate market volatility while executing on our strategy. We are maintaining our annual guidance for 2026 on an adjusted basis. For the second quarter, we project revenue between $330 million and $360 million, with earnings per share in the range of $0.15 to $0.25.”
Conference Call
The Nu Skin Enterprises management team will host a conference call with the investment community today at 5 p.m. (ET). Those wishing to access the webcast, as well as the financial information presented during the call, can visit the Investor Relations page on the company's website at ir.nuskin.com
. A replay of the webcast will be available on the same page through May 21, 2026.
About Nu Skin Enterprises Inc.
Nu Skin Enterprises Inc.
(NYSE: NUS) is an intelligent beauty and wellness company, powered by a dynamic affiliate opportunity platform, which operates in nearly 50 markets worldwide. Backed by more than 40 years of scientific research, the company’s products help people look, feel and live their best with our newly introduced Prysm iO intelligent wellness platform, an award-winning line of beauty device systems and trusted brands in personal care and wellness products. Rhyz is the strategic investment arm of Nu Skin Enterprises, formed in 2018 consisting of synergistic consumer, technology and manufacturing companies focused on innovation within the beauty, wellness and lifestyle categories.
Important Information Regarding Forward-Looking Statements: This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that represent the company’s current expectations and beliefs. All statements other than statements of historical fact are “forward-looking statements” for purposes of federal and state securities laws and include, but are not limited to, statements of management’s expectations regarding the company’s performance, growth, initiatives, plans, areas of focus, sales force and customers, shareholder value, Prysm launch and its timing and potential benefits to the business, and emerging market expansion and its timing; projections regarding revenue, expenses, margins, tax rates, earnings per share, foreign currency fluctuations, uses of cash, financial position and other financial items; statements of belief; and statements of assumptions underlying any of the foregoing. In some cases, you can identify these statements by forward-looking words such as “believe,” “expect,” “become,” “continue,” “project,” “outlook,” “guidance,” “focus,” “expand,” “will,” “would,” “could,” “may,” “might,” the negative of these words and other similar words.
The forward-looking statements and related assumptions involve risks and uncertainties that could cause actual results and outcomes to differ materially from any forward-looking statements or views expressed herein. These risks and uncertainties include, but are not limited to, the following:
· any failure of current or planned initiatives or products to generate interest among the company’s sales force and customers and generate sponsoring and selling activities on a sustained basis;
· risk that direct selling laws and regulations in any of the company’s markets, including the United States and Mainland China, may be modified, interpreted or enforced in a manner that results in negative changes to the company’s business model or negatively impacts its revenue, sales force or business, including through the interruption of sales activities, loss of licenses, increased scrutiny of sales force actions, imposition of fines, or any other adverse actions or events;
· economic conditions and events globally;
· the company’s future tax-planning initiatives, any prospective or retrospective increases in duties or tariffs on the company’s products imported into the company’s markets, and any adverse results of tax audits or unfavorable changes to tax laws in the company’s various markets;
· competitive pressures in the company’s markets;
· risk that epidemics or other crises, as well as any related disruptions, could negatively impact our business;
· adverse publicity related to the company’s business, products, industry or any legal actions or complaints by the company’s sales force or others;
· political, legal, tax and regulatory uncertainties, including trade policies, associated with operating in Mainland China and other international markets;
· uncertainty regarding meeting restrictions and other government scrutiny in Mainland China, as well as negative media and consumer sentiment in Mainland China on our business operations and results;
· risk of foreign-currency fluctuations and the currency translation impact on the company’s business associated with these fluctuations;
· uncertainties regarding the future financial performance of the businesses the company has acquired;
· risks related to accurately predicting, delivering or maintaining sufficient quantities of products to support planned initiatives or launch strategies, and increased risk of inventory write-offs if the company over-forecasts demand for a product or changes its planned initiatives or launch strategies; and
· regulatory risks associated with the company’s products, which could require the company to modify its claims or inhibit its ability to import or continue selling a product in a market if the product is determined to be a medical device or if the company is unable to register the product in a timely manner under applicable regulatory requirements.
The company’s financial performance and the forward-looking statements contained herein are further qualified by a detailed discussion of associated risks set forth in the documents filed by the company with the Securities and Exchange Commission. The forward-looking statements set forth the company’s beliefs as of the date that such information was first provided, and the company assumes no duty to update the forward-looking statements contained in this release to reflect any change except as required by law.
Non-GAAP Financial Measures: Constant-currency revenue change is a non-GAAP financial measure that removes the impact of fluctuations in foreign-currency exchange rates, thereby facilitating period-to-period comparisons of the company’s performance. It is calculated by translating the current period’s revenue at the same average exchange rates in effect during the applicable prior-year period and then comparing that amount to the prior-year period’s revenue. The company believes that constant-currency revenue change is useful to investors, lenders and analysts because such information enables them to gauge the impact of foreign-currency fluctuations on the company’s revenue from period to period.
Earnings per share, gross margin, general and administrative expenses, and operating margin, each excluding inventory write-off charges, impairment expense, the gain from the Mavely sale, unrealized investment loss, and/or other charges, also are non-GAAP financial measures.
· Inventory write-off charges, impairment expense, and unrealized investment loss are not part of the ongoing operations of our underlying business; and
· the gain from the Mavely sale, and the other charges incurred in connection with this sale and other corporate actions, are not part of our ongoing operations.
The company believes that these non-GAAP financial measures are useful to investors, lenders and analysts because removing the impact of these items facilitates period-to-period comparisons of the company’s performance. Please see the reconciliations of these items to our earnings per share, gross margin, operating margin, income tax rate and revenue growth rate calculated under GAAP, below.
The following table sets forth revenue for the three-month periods ended March 31, 2026, and 2025 for each of our reportable segments (U.S. dollars in thousands):
| | | | | | | | | | | | | | | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| | Three Months Ended | | | | | | | | | | | | | Constant- | |
| | March 31, | | | | | | | | | | | | | Currency | |
| | | 2026 | | | | 2025 | | | | Change | | | | Change | |
| Nu Skin | | | | | | | | | | | | | | | |
| Americas | $ | 57,818 | | | $ | 69,058 | | | | (16.3 | )% | | | (12.6 | )% |
| Southeast Asia/Pacific | | 45,474 | | | | 52,172 | | | | (12.8 | )% | | | (16.6 | )% |
| Mainland China | | 45,148 | | | | 47,775 | | | | (5.5 | )% | | | (10.0 | )% |
| Japan | | 39,739 | | | | 42,765 | | | | (7.1 | )% | | | (4.3 | )% |
| Europe & Africa | | 31,218 | | | | 33,021 | | | | (5.5 | )% | | | (14.8 | )% |
| Hong Kong/Taiwan | | 27,457 | | | | 28,447 | | | | (3.5 | )% | | | (5.9 | )% |
| South Korea | | 25,329 | | | | 32,515 | | | | (22.1 | )% | | | (21.4 | )% |
| Nu Skin Other | | (234 | ) | | | 529 | | | | (144.2 | )% | | | (144.4 | )% |
| Total Nu Skin | | 271,949 | | | | 306,282 | | | | (11.2 | )% | | | (12.5 | )% |
| Rhyz | | | | | | | | | | | | | | | |
| Manufacturing | | 44,925 | | | | 55,290 | | | | (18.7 | )% | | | (18.7 | )% |
| Rhyz Other | | 3,734 | | | | 2,918 | | | | 28.0 | % | | | 28.0 | % |
| Total Rhyz | | 48,659 | | | | 58,208 | | | | (16.4 | )% | | | (16.4 | )% |
| Total | $ | 320,608 | | | $ | 364,490 | | | | (12.0 | )% | | | (13.1 | )% |
The following table provides information concerning the number of Customers, Paid Affiliates and Sales Leaders in our core Nu Skin business for the three-month periods ended March 31, 2026 and 2025:
| | | | | | | | | | | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| | Three Months Ended | | | | | | | | | | |
| | March 31, | | | | | | | | | | |
| | | 2026 | | | | 2025 | | | | Change | |
| Customers | | | | | | | | | | | |
| Americas | | 186,448 | | | | 227,514 | | | | (18 | )% |
| Southeast Asia/Pacific | | 67,461 | | | | 74,584 | | | | (10 | )% |
| Mainland China | | 104,721 | | | | 122,474 | | | | (14 | )% |
| Japan | | 102,392 | | | | 107,742 | | | | (5 | )% |
| Europe & Africa | | 115,343 | | | | 130,154 | | | | (11 | )% |
| Hong Kong/Taiwan | | 35,899 | | | | 42,523 | | | | (16 | )% |
| South Korea | | 57,271 | | | | 71,721 | | | | (20 | )% |
| Total Customers | | 669,535 | | | | 776,712 | | | | (14 | )% |
| Paid Affiliates | | | | | | | | | | | |
| Americas | | 27,039 | | | | 26,936 | | | | 0 | % |
| Southeast Asia/Pacific | | 18,163 | | | | 22,296 | | | | (19 | )% |
| Mainland China | | 18,064 | | | | 19,859 | | | | (9 | )% |
| Japan | | 19,224 | | | | 21,073 | | | | (9 | )% |
| Europe & Africa | | 13,607 | | | | 15,184 | | | | (10 | )% |
| Hong Kong/Taiwan | | 9,541 | | | | 9,622 | | | | (1 | )% |
| South Korea | | 15,212 | | | | 16,548 | | | | (8 | )% |
| Total Paid Affiliates | | 120,850 | | | | 131,518 | | | | (8 | )% |
| Sales Leaders | | | | | | | | | | | |
| Americas | | 4,930 | | | | 6,174 | | | | (20 | )% |
| Southeast Asia/Pacific | | 3,769 | | | | 4,542 | | | | (17 | )% |
| Mainland China | | 5,489 | | | | 6,214 | | | | (12 | )% |
| Japan | | 5,943 | | | | 6,210 | | | | (4 | )% |
| Europe & Africa | | 2,314 | | | | 2,839 | | | | (19 | )% |
| Hong Kong/Taiwan | | 2,123 | | | | 2,207 | | | | (4 | )% |
| South Korea | | 2,347 | | | | 2,850 | | | | (18 | )% |
| Total Sales Leaders | | 26,915 | | | | 31,036 | | | | (13 | )% |